Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Metabolic Effects of Switching From Injectable Semaglutide to Tirzepatide: A Retrospective Study of the LMC Diabetes Registry

NCT07889453 is registered in ClinicalTrials.gov with LMC Diabetes & Endocrinology Ltd. as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07889453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Metabolic Effects of Switching From Injectable Semaglutide to Tirzepatide: A Retrospective Study of the LMC Diabetes Registry
Lead sponsor
LMC Diabetes & Endocrinology Ltd.
Phase
Observational
Overall status
Active, not recruiting
Start date
October 15, 2026
Completion date
June 30, 2027
Enrollment
650 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, type 2 diabetes (t2d)

Arms

As registered; 3 arms.

  • T2D Switch TZP Cohort Tirzepatide

    adults living with T2D who switched from injectable semaglutide to tirzepatide

  • Obesity Switch TZP Cohort Tirzepatide

    adults living with obesity without diabetes, who switched from injectable semaglutide and to tirzepatide

  • T2D SEMA Cohort

    adults living with T2D who were prescribed injectable semaglutide and did not switch to tirzepatide

Primary endpoints

Registered primary outcome measures; 2 primary.

  • Change from Baseline in Body Weight at 12 Months - T2D Switch TZP Cohort Baseline to follow-up (6-12 months)

    Change in body weight (kg) at 6-12-month follow-up (closest observation to 12 month follow-up, ±6 weeks) compared to baseline (closest observation to the index date, ±6 weeks) among individuals living with T2D who switched from injectable semaglutide to tirzepatide during the index period.

  • Change from Baseline in Body Weight at 12 Months - Obesity Switch TZP Cohort Baseline to follow-up (6-12 months)

    Change in body weight (kg) at 6-12-month follow-up (closest observation to 12 month follow-up, ±6 weeks) compared to baseline (closest observation to the index date, ±6 weeks) among individuals living with obesity (non-diabetes) who switched from injectable semaglutide to tirzepatide during the index period.

Lead sponsor's other trials

LMC Diabetes & Endocrinology Ltd., most recent start first.

Similar trials

Same condition (Diabetes Mellitus, Type 2) and phase, most recent start first.